The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.
J. P. Connor
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
R. Stupp
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
M. C. Cristea
No relevant relationships to disclose
N. Lewis
No relevant relationships to disclose
L. D. Lewis
Research Funding - Merck KGaA
M. R. Mattiacci
Employment or Leadership Position - Merck Serono
M. Felder
No relevant relationships to disclose
S. Stewart
No relevant relationships to disclose
J. Henslee-Downey
Employment or Leadership Position - EMD Serono
R. Neugebauer
Employment or Leadership Position - Merck KGaA
P. B. Komarnitsky
Employment or Leadership Position - EMD Serono